Evaluation of a 6-year highly active antiretroviral therapy in Chinese HIV-1-infected patients

Intervirology

Volumn 53, Issue 4, 2010, Pages 240-246

  Zhou, Hua Ying ^a   Zheng, Yu Huang ^a   He, Yan ^a   Chen, Zi ^a   Liu, Meng ^a   Yin, Wei ^a   Liu, Chun ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Antiretroviral therapy; Chinese HIV patients; HIV 1 treatment; Long term antiretroviral therapy; Nevirapine; Tolerability

Indexed keywords

DIDANOSINE; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ABDOMINAL FULLNESS; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM DISEASE; CHINESE; CHOLESTEROL BLOOD LEVEL; DIARRHEA; DIZZINESS; DROWSINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INSOMNIA; LACTIC ACIDOSIS; LIPODYSTROPHY; LIVER INJURY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; PARESTHESIA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; SIDE EFFECT; T LYMPHOCYTE SUBPOPULATION; TRIACYLGLYCEROL BLOOD LEVEL; VIREMIA; VOMITING;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHINA; CHOLESTEROL; FEMALE; FOLLOW-UP STUDIES; GAMMA-GLUTAMYLTRANSFERASE; HIV INFECTIONS; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; RNA, VIRAL; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME; TRIGLYCERIDES; VIRAL LOAD; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77950056676     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000302762     Document Type: Article

References (21)

1. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ: Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135: 17-26.
2. Van Sighem AI, Van De Wiel MA, Ghani AC, Jambroes M, Reiss P, Gyssens IC, Brinkman K, Lange JM, de Wolf: Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS 2003; 17: 2227-2236. (Pubitemid 37338896)
3. Zhou HY, Zheng YH, Yang X, Gong GZ, Chang HW, Zhong FY, Zou W: A Twentyfour week clinical trial using didanosine, stavudine and nevirapine for highly active antiretroviral therapy. J Chin Physician 2003; 5: 1592-1595.
4. Zhou HY, Zheng YH, Zhang CY, Ding PP, Zou W: A one-year clinical trial using didanosine, stavudine and nevirapine for highly active antiretroviral therapy. Chin Med J (Engl) 2005; 118: 609-611.
5. Zhou HY, Zheng YH, Zhang CY, et al: Evaluation of human immunodeficiency virus type 1-infected Chinese patients treated with highly active antiretroviral therapy for two years. Viral Immunol 2007; 20: 180-187.
6. Zheng YH, Cheng J, Lei JH, Lai LY, Zhu YH, He Y, Luo HY, Zhou HY, Ding PP, Zhang CY, Li H : Immunological change in HIV-1-infected patients treated with highly active antiretroviral therapy. Chin J Dermatol 2006; 39: 42-46.
7. Valdez H, Connick E, Smith KY, Lederman MM, Bosch RJ, Kim RS, St Clair M, Kuritzkes DR, Kessler H, Fox L, Blanchard-Vargas M, Landay A: Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002; 16: 1859-1866.
8. Ungsedhapand C, Srasuebkul P, Cardiello P, Ruxrungtham K, Ratanasuwan W, Kroon ED, Tongtalung M, Juengprasert N, Ubolyam S, Siangphoe U, Emery S, Lange JM, Cooper DA, Phanuphak P: Three year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection. J Acquir Immune Defic Syndr 2004; 36: 693-701.
9. Gulick RM, Mellors JW, Havlir D, Eron JJ, Meibohm A, Condra JH, Valentine FT, Mc- Mahon D, Gonzalez C, Jonas L, Emini EA, Chodakewitz JA, Isaacs R, Richman DD: Three-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med 2000; 133: 35-39.
10. Resino S, Resino R, Micheloud D, Gurbindo Gutiérrez D, Léon JA, Ramos JT, Ciria L, de José I, Mellado J, Muñoz- Fernández A: Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of followup. Clin Infect Dis 2006; 42: 862-869.
11. Viard JP, Burgard M, Hubert JB, Aaron L, Rabian C, Pertuiset N, Lourenço M, Rothschild C, Rouzioux C: Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS 2004; 18: 45-49.
12. Smith K, Aga E, Bosch RJ, Valdez H, Connick E, Landay A, Kuritzkes D, Gross BH, Francis IR, McCune JM, Kessler H, Lederman M: Long-term changes in circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretroviral therapy. AIDS 2004; 18: 1953-1956.
13. Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, Seage GR 3rd: Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis 2008; 46; 507-515. (Pubitemid 351263487)
14. World Health Organization (WHO): Scaling Up Antiretroviral Therapy in Resource- Limited Settings: Treatment Guidelines for a Public Health Approach - 2006 revision. Geneva, WHO, 2006. http://www.who.int/hiv/ pub/guidelines/art/en/ index.html (accessed November 9, 2006).
15. Gulick RM, Meibohm A, Havlir D, Eron JJ, Mosley A, Chodakewitz JA, Isaacs R, Gonzalez C, McMahon D, Richman DD, Robertson M, Mellors JW: Six-year follow-up of HIV-1- infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS 2003; 17: 2345-2349.
16. Kaufmann GR, Bloch M, Finlayson R, Zaunders J, Smith D, Cooper DA: The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy. AIDS 2002; 16: 359-367.
17. Tarwater PM, Margolick JB, Jin J, Phair JP, Detels R, Rinaldo C, Giorgi J, Muñoz A: Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27: 168-175.
18. Hunt PW, Deeks SG, Rodriguez B, Valdez H, Shade SB, Abrams DI, Kitahata MM, Krone M, Neilands TB, Brand RJ, Lederman MM, Martin JN: Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003; 17: 1907-1915.
19. Franco JM, Leon-Leal JA, Leal M, Cano-Rodriguez A, Pineda JA, Macias J, Rubio A, Rey C, Sanchez B, Lissen E: CD4+ and CD8+ T lymphocyte regeneration after anti-retroviral therapy in HIV-1-infected children and adult patients. Clin Exp Immunol 2000; 119: 493-498.
20. Shu-Yun Wu: Seborrheic baldness due to lamivudine. Adverse Drug Reactions J 2005; 3: 230.
21. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA: Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-2099.